NSRX Nasus Pharma Ltd Annual reports only
Pharmaceutical Preparations · NYSE · SEC CIK 2029039 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-282.2%
TTM EPS YoY-227.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-0.4%
Net margin-0.5%
FCF margin-0.4%
EBITDA margin—
Returns
ROE—
ROA-204.7%
ROIC (approx.)—
Asset turnover431.74x
Leverage & solvency
Liabilities / assets44.7%
Debt / equity0.00x
Current ratio2.24x
Interest coverage62.87x
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-32.8%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $1.24B | — | — |
| R&D expense | $2.24M | $335,000 | $567,000 |
| SG&A expense | $2.67M | $743,000 | $580,000 |
| Operating income | -$4.90M | -$1.08M | -$1.15M |
| Interest expense | -$78,000 | $29,000 | $49,000 |
| Net income | -$5.86M | -$1.53M | -$1.05M |
| EPS (basic) | -0.72 | -0.22 | -0.15 |
| EPS (diluted) | -0.72 | -0.22 | -0.20 |
| Weighted avg. shares (diluted) | 8.01M | 7.03M | 7.06M |
| Balance sheet | |||
| Cash & equivalents | $1.24M | $284,000 | $193,000 |
| Current assets | $4.86M | $457,000 | — |
| PP&E, net | $14,000 | — | — |
| Total assets | $5.00M | $717,000 | — |
| Current liabilities | $2.16M | $3.93M | — |
| Total liabilities | $2.24M | $3.93M | — |
| Shareholders' equity | $2.77M | -$3.21M | -$3.80M |
| Shares outstanding | 9.02M | 7.36M | — |
| Cash flow statement | |||
| Operating cash flow | -$4.92M | -$665,000 | -$1.03M |
| Capital expenditure | $14,000 | — | — |
| Free cash flow | -$4.93M | — | — |
| Investing cash flow | -$3.01M | — | — |
| Financing cash flow | $8.92M | $770,000 | $1.05M |
| Stock-based compensation | $447,000 | $10,000 | $39,000 |
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.